Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-ARC002 in Locally Advanced or Metastatic Solid Tumors
NCT07591155Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-ARC002 in solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 42 days, Maximum Tolerated Dose at 42 days and 1 more. Started May 2026; status: recruiting.
02
Drugs
BL-ARC002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07591155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591155.